A detailed history of First Republic Investment Management, Inc. transactions in Genmab A/S stock. As of the latest transaction made, First Republic Investment Management, Inc. holds 38,304 shares of GMAB stock, worth $963,345. This represents 0.0% of its overall portfolio holdings.

Number of Shares
38,304
Holding current value
$963,345
% of portfolio
0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 07, 2023

BUY
$35.27 - $42.24 $1.35 Million - $1.62 Million
38,304 New
38,304 $1.35 Million
Q1 2023

May 11, 2023

SELL
$34.88 - $43.22 $21,730 - $26,926
-623 Reduced 1.08%
57,309 $2.16 Million
Q4 2022

Feb 13, 2023

SELL
$33.8 - $47.06 $427,468 - $595,167
-12,647 Reduced 17.92%
57,932 $2.46 Million
Q3 2022

Nov 03, 2022

SELL
$31.52 - $373.61 $99,823 - $1.18 Million
-3,167 Reduced 4.29%
70,579 $2.27 Million
Q2 2022

Aug 16, 2022

BUY
$26.83 - $38.57 $369,127 - $530,646
13,758 Added 22.93%
73,746 $2.4 Million
Q1 2022

May 16, 2022

BUY
$30.95 - $39.68 $178,210 - $228,477
5,758 Added 10.62%
59,988 $2.17 Million
Q4 2021

Feb 09, 2022

BUY
$35.87 - $47.12 $23,494 - $30,863
655 Added 1.22%
54,230 $2.15 Million
Q3 2021

Nov 12, 2021

BUY
$41.55 - $48.72 $100,592 - $117,951
2,421 Added 4.73%
53,575 $2.34 Million
Q2 2021

Aug 16, 2021

BUY
$32.88 - $44.57 $255,872 - $346,843
7,782 Added 17.94%
51,154 $2.09 Million
Q1 2021

May 14, 2021

SELL
$30.92 - $44.4 $73,929 - $106,160
-2,391 Reduced 5.22%
43,372 $1.42 Million
Q4 2020

Feb 16, 2021

BUY
$33.66 - $40.76 $161,904 - $196,055
4,810 Added 11.75%
45,763 $1.86 Million
Q3 2020

Nov 12, 2020

BUY
$33.07 - $38.68 $941,833 - $1.1 Million
28,480 Added 228.33%
40,953 $1.5 Million
Q2 2020

Aug 13, 2020

SELL
$20.05 - $33.89 $28,070 - $47,446
-1,400 Reduced 10.09%
12,473 $423,000
Q1 2020

May 13, 2020

BUY
$17.15 - $25.22 $237,921 - $349,877
13,873 New
13,873 $294,000

Others Institutions Holding GMAB

About GENMAB A/S


  • Ticker GMAB
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 658,292,992
  • Market Cap $16.6B
  • Description
  • Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...
More about GMAB
Track This Portfolio

Track First Republic Investment Management, Inc. Portfolio

Follow First Republic Investment Management, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of First Republic Investment Management, Inc., based on Form 13F filings with the SEC.

News

Stay updated on First Republic Investment Management, Inc. with notifications on news.